This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

Autorentext

Priya Hays, Ph.D. is an accomplished science writer, having written and published three books. Her latest book Advancing Healthcare Through Personalized Medicine is a monograph on the implementation of the latest advances in precision medicine, with a second edition due out soon. She has authored over fifteen publications in journals as varied as the Bulletin of Science, Technology and Society, L'Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, Journal of Clinical Investigation and Studies and collaboration on adverse effects of CAR T-cell therapy with two physicians from the University of California, San Diego Health System in Future Oncology. She is an elected member of the American Society of Clinical Oncology, American College of Medical Genetics and Genomics, and the Society for Immunotherapy of Cancer. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego.

Inhalt

PrefaceIntroduction Chapter 1: The History and Development of Cancer ImmunotherapiesChapter 2: Clinician-inspired questions for refining the mechanisms of action of checkpoint inhibitorsChapter 3: Promising Prospects of Chimeric Antigen Receptor T Cell Therapy for Glioblastoma MultiformeChapter 4: Cancer Immunotherapies for Melanoma Chapter 5: Combining BRAF/MEK-Targeted Therapy with Immunotherapy in MelanomaChapter 6: Lag3: From Bench to BedsideChapter 7: Immune-based therapeutic interventions for Acute Myeloid LeukemiaChapter 8: Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolutionChapter 9: Role of Immunotherapy as second line in advanced pancreatic cancerChapter 10: The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cellsChapter 11: Tumor antigen-specific allogeneic T cells for broadly applicable adoptive cell therapy of cancerChapter 12: Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity